Latest News & Features

Reset all filters
Article Type
Channels & Sectors
Geography
Company

Refine Search
Medtech
Now that Costa Rica has allowed adult stem cells to be used as part of regenerative therapies, the country should be able to attract more investment, say María del Pilar López and Esteban Monge of Zürcher Lawyers.   4 July 2017
Genetics
Despite their great ability to fight diseases, gene therapies face tough challenges from an IP and regulatory perspective in Mexico, as Hector Chagoya and Mariana Gonzalez of Becerril, Coca & Becerril report.   3 July 2017
Biotechnology
An advice system for labelling products in Mexico has been extended to food and non-alcoholic beverages. Daniel Sanchez and Victor Ramirez of Olivares report on how the regime works in practice.   30 June 2017
Europe
Almost one year after the US Supreme Court’s Halo decision, companies should consider a handful of best practices to reduce the risk of paying enhanced damages for wilful patent infringement, as Lynde Herzbach of Birch Stewart Kolasch Birch reports.   30 June 2017
Genetics
Marisa Moura Momoli of Di Blasi, Parente & Associados looks at the fast-developing CRISPR/Cas9 technology and discusses its patentability in Brazil.   29 June 2017
article
Two decisions in India on the protection of plant varieties provide useful guidance in this area, as Archana Shanker of Anand and Anand reports.   29 June 2017
Europe
Spain’s new patent law came into force on April 1, and it contains a few measures which will affect pharmaceutical companies, says Dámaso Gallardo of Clarke Modet & Co.   28 June 2017
Biotechnology
The formal requirements for priority have become a hot topic at the European Patent Office, driven by their importance in high-profile oppositions to the Broad Institute’s CRISPR/Cas9 patents, as Catherine Coombes of HGF explains.   28 June 2017
Europe
Collaboration and sharing are important goals for Bayer in seeking to protect innovations with IP rights, as Richard Rees explains in an interview with LSIPR.   22 June 2017
Europe
With the US Supreme Court set to decide the biosimilars dispute between Amgen and Sandoz, LSIPR examines the possible outcomes and implications for those in the industry.   21 June 2017